Mark Iwicki

Mark Iwicki is a Director of Oxeia Biopharmaceuticals. Mr. Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas.

Mr. Iwicki has extensive experience building businesses and has been instrumental in the success of a number of multi-billion dollar products. Mr Iwicki is Chairman and CEO of Kala Pharmaceuticals. Prior to Kala, Mr. Iwicki was CEO of Civitas Therapeutics, which was sold to Acorda Therapeutics in 2014. Before joining Civitas, he was President and CEO of Blend Therapeutics. He also served as President and CEO of Sunovion Pharmaceuticals, where he provided leadership for the successful launch of that company, which was created following the acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. Mr. Iwicki previously held key senior leadership roles with Sepracor and Novartis Pharmaceuticals. He currently sits on the Board of Directors for Aimmune Therapeutics, Kala Pharmaceuticals, Pulmatrix, Nimbus Therapeutics, Merus and Taris Biomedical.